Gynecologic Oncology & Benign Pelvic Pathology

Endometrial Carcinoma is the most common gynecologic malignancy in developed nations, presenting in 90% of cases with Postmenopausal Vaginal Bleeding (or heavy/intermenstrual abnormal uterine bleeding in premenopausal women). Over 80% of cases are Type I Endometrioid Adenocarcinomas (PTEN and mismatch-repair Lynch syndrome mutations), driven by chronic Unopposed Estrogen exposure—specifically Obesity (peripheral adipose aromatase converts adrenal androstenedione into estrone), Chronic Anovulation / PCOS (lack of corpus luteum progesterone!), Nulliparity, Early Menarche / Late Menopause, Tamoxifen therapy (SERM acting as an estrogen agonist on the endometrium), or an Estrogen-Secreting Granulosa Cell Ovarian Tumor (conversely, Type II Serous/Clear-Cell carcinomas arise in older women from atrophic endometrium via TP53 mutations with Psammoma bodies and poor prognosis, while multiparity, combined OCPs, progestin IUDs, and smoking are protective against Type I!). CRITICAL DIAGNOSTIC CUTOFFS: (1) Any woman ≥45 years old presenting with Abnormal Uterine Bleeding—OR any woman <45 years old with AUB plus unopposed estrogen risk factors (obesity/PCOS)—requires an Endometrial Biopsy! (2) In any Postmenopausal woman with vaginal bleeding, perform either an Endometrial Biopsy OR a Transvaginal Ultrasound (TVUS): if endometrial stripe thickness on TVUS is >4 mm (or bleeding persists), an Endometrial Biopsy is mandatory! Endometrial hyperplasia without atypia is treated with Progestins (Levonorgestrel IUD or oral medroxyprogesterone), whereas hyperplasia WITH atypia (EIN) or Endometrial Carcinoma requires Total Hysterectomy with Bilateral Salpingo-Oophorectomy (TAH-BSO). For Cervical Cancer Screening (driven by high-risk HPV types 16 and 18, where viral oncoprotein E6 degrades p53 and E7 inhibits Rb at the squamocolumnar transformation zone): start screening at Age 21 (never screen under 21 regardless of sexual debut!): Ages 21–29 → Pap cytology alone every 3 years; Ages 30–65 → Primary HPV testing every 5 years, Co-testing (Pap + HPV) every 5 years, or Pap alone every 3 years (stop at age 65 if adequate negative prior screening and no CIN2+ in 20 years). Any HSIL, ASC-H, AGC, or HPV 16/18+ result requires immediate Colposcopy with Ectocervical Biopsy and Endocervical Curettage (ECC — note: ECC is STRICTLY CONTRAINDICATED in Pregnancy!).

Ovarian neoplasms are classified by their cellular origin into three distinct families that appear on every board exam: (1) Surface Epithelial Tumors (70% of ovarian tumors, >90% of malignant ovarian cancers; monitored with CA-125) occur in postmenopausal women (risk increased by BRCA1/BRCA2 mutations, Lynch syndrome, nulliparity, and endometriosis [associated with endometrioid and clear-cell ovarian cancer]; risk reduced by combined OCPs, multiparity, breastfeeding, and tubal ligation/salpingectomy because decrease in ovulatory cycles reduces cortical inclusion cyst rupture!): Serous Cystadenocarcinoma is the #1 malignant ovarian cancer (frequently bilateral, peritoneal carcinomatosis with omental caking, and concentric laminated calcified Psammoma Bodies); Mucinous Cystadenocarcinoma secretes mucin and can arise from appendiceal metastasis causing jelly-like ascites (Pseudomyxoma Peritonei); and Brenner Tumor is a benign transitional-cell tumor with 'Coffee-Bean' grooved nuclei. (2) Germ Cell Tumors (adolescents and young women aged 10–30; monitored with tumor markers!): Mature Cystic Teratoma (Dermoid Cyst) is the #1 ovarian tumor in young women (benign 46,XX tumor containing hair, sebaceous sebum, and calcified teeth that predisposes to Ovarian Torsion; variant Struma Ovarii contains functional thyroid tissue causing hyperthyroidism with low radioiodine uptake in the neck!); Dysgerminoma is the #1 malignant germ cell tumor in young women (homologue of testicular seminoma; 'fried-egg' cells, placental ALP [PLAP] and Elevated LDH and/or hCG; associated with Turner syndrome 45,XO/46,XY mosaicism; radiosensitive); Yolk Sac (Endodermal Sinus) Tumor is the most aggressive germ cell tumor in children/young women (secretes Alpha-Fetoprotein [AFP] and shows pathognomonic perivascular Schiller-Duval Bodies resembling glomeruli); and Non-Gestational Choriocarcinoma secretes β-hCG. (3) Sex Cord–Stromal Tumors: Granulosa Cell Tumor secretes Estrogen and Inhibin (causing precocious puberty in young girls OR endometrial hyperplasia/postmenopausal bleeding in older women) and displays rosettes of cells around eosinophilic fluid spaces (Call-Exner Bodies); Sertoli-Leydig Cell Tumor secretes Androgens (testosterone) causing acute virilization (hirsutism, clitoromegaly, deepening voice, male-pattern balding) with Reinke crystals; and benign Ovarian Fibroma (bundles of spindle fibroblasts) causes Meigs Syndrome: the triad of Benign Ovarian Fibroma + Ascites + Right-Sided Pleural Effusion that resolves completely upon tumor removal!

Compare Endometriosis and Adenomyosis directly by bimanual pelvic exam and pathogenesis: (1) Endometriosis is the presence of functional endometrial glands and stroma outside the uterus—most commonly implanted on the Ovaries (forming bilateral 'Chocolate Cysts' [Endometriomas] filled with dark brown hemosiderin-laden blood), Posterior Cul-de-Sac (Pouch of Douglas), Uterosacral Ligaments, and Rectovaginal Septum (driven by retrograde menstruation [Sampson theory], coelomic metaplasia, or lymphatic spread). Patients present in their 20s–30s with the classic '4 D's': Dysmenorrhea (cyclic pelvic pain beginning 1–2 days before menses), deep Dyspareunia (pain with deep vaginal penetration from uterosacral ligament nodules), Dyschizia (painful defecation during menses from rectovaginal cul-de-sac implants), and Infertility (#1 cause of anatomic/inflammatory tubal distortion in otherwise asymptomatic infertile women!). Crucially, on bimanual pelvic examination in Endometriosis, the uterus is NORMAL IN SIZE, often retroverted and fixed/immobile, with tender uterosacral nodularity and adnexal endometrioma fullness. Transvaginal ultrasound identifies ovarian endometriomas ('ground-glass' homogeneous echogenicity), while Definitive Diagnosis requires Direct Laparoscopic Visualization and Biopsy showing red/blue/black 'powder-burn / gunpowder' peritoneal lesions and hemosiderin-laden macrophages. Treat endometriosis medically with NSAIDs + Combined Estrogen-Progestin Contraceptives (or Continuous Progestins / Levonorgestrel IUD) as first-line, escalating to GnRH Agonists (Leuprolide, which downregulates pituitary GnRH receptors to create a pseudomenopausal hypoestrogenic state; add back low-dose norethindrone to prevent bone loss!) or GnRH Antagonists (Elagolix/Relugolix), or laparoscopic excision/ablation for infertility. (2) Adenomyosis occurs in multiparous women aged 35–50 when the basal layer of the endometrium invades directly into the underlying myometrium, inducing myometrial hypertrophy: patients present with severe Dysmenorrhea AND Heavy Menstrual Bleeding (Menorrhagia), and bimanual exam reveals a UNIFORMLY (SYMMETRICALLY) ENLARGED, GLOBULAR, SOFT ('BOGGY'), TENDER UTERUS! Diagnose non-invasively with TVUS or Pelvic MRI (junctional zone thickening >12 mm), manage medically with a Levonorgestrel IUD or combined OCPs, and cure definitively with Hysterectomy.

Uterine Leiomyomas (Fibroids) are the most common pelvic tumors in women (highest prevalence in African American women), representing benign monoclonal proliferations of uterine smooth muscle cells and extracellular matrix collagen/fibronectin responsive to both Estrogen and Progesterone (fibroids enlarge during reproductive years and pregnancy, and shrink after menopause!). On bimanual pelvic exam, fibroids produce an ASYMMETRICALLY ENLARGED, IRREGULARLY CONTOURED, FIRM ('RUBBERY'), NON-TENDER UTERUS. Clinical presentation depends strictly on the anatomical layer of the fibroid: (1) Submucosal Fibroids (protruding directly into the endometrial cavity) are the most likely to cause Heavy Menstrual Bleeding (Menorrhagia with iron deficiency anemia), Recurrent Miscarriage, and Infertility (diagnosed via Saline Infusion Sonohysterography or Hysteroscopy and treated via Hysteroscopic Myomectomy!); (2) Intramural Fibroids (within the muscular wall, #1 location) cause heavy menstrual bleeding, pelvic pressure, and uterine enlargement; and (3) Subserosal Fibroids (projecting outward from the serosa) do not cause heavy bleeding, but cause bulk-related compression symptoms (anterior bladder compression → urinary frequency; posterior rectal compression → constipation; or pedunculated torsion). During the 2nd trimester of pregnancy, rapid fibroid growth can outstrip its blood supply, causing Carneous ('Red') Degeneration (Fibroid Infarction)—presenting with acute localized uterine pain, low-grade fever, leukocytosis, and nausea/vomiting, which is managed conservatively with rest and short-term analgesia (Indomethacin if <32w / Acetaminophen)—NEVER perform a myomectomy during pregnancy due to catastrophic hemorrhage risk! Outside of pregnancy, medical management uses Tranexamic Acid, Combined OCPs, Levonorgestrel IUD, or short-term preoperative GnRH Agonists (Leuprolide) / GnRH Antagonists (Relugolix/Elagolix) to shrink fibroid volume and correct anemia prior to Myomectomy (for women desiring future fertility) or Uterine Artery Embolization / Hysterectomy.

During colposcopy, applying 3–5% acetic acid turns dysplastic epithelium white (acetowhite changes) and reveals abnormal angiogenesis (punctation, mosaicism, atypical vessels). Biopsy-proven CIN 1 is managed with observation and repeat testing in 1 year. Biopsy-proven high-grade dysplasia (CIN 2 or CIN 3) in patients aged ≥25 requires excisional ablation of the transformation zone via Loop Electrosurgical Excision Procedure (LEEP) or Cold-Knife Conization (CKC). Specifically, diagnostic/therapeutic Conization is mandatory when: (1) the entire squamocolumnar junction or lesion cannot be visualized on colposcopy (unsatisfactory colposcopy); (2) the Endocervical Curettage (ECC) is positive for CIN 2/3; (3) there is a major discrepancy between a high-grade Pap (HSIL) and a negative biopsy; or (4) Adenocarcinoma in situ (AIS) or microinvasive cancer is suspected. Note that conization/LEEP carries an obstetric risk of cervical insufficiency and second-trimester preterm birth.

Invasive cervical carcinoma classically presents in an unscreened patient with postcoital vaginal bleeding, watery foul-smelling discharge, or pelvic pain. Locally advanced tumor invades anteriorly into the bladder base or laterally through the cardinal ligaments into the parametrium and pelvic sidewall, compressing the distal ureters and causing bilateral hydronephrosis and postrenal uremic kidney failure (the #1 direct cause of death in advanced cervical cancer!). Early-stage disease (Stage IA–IB2) is treated with radical hysterectomy plus pelvic lymphadenectomy (or radical trachelectomy to preserve fertility in small tumors), whereas locally advanced disease (Stage IIB–IVA: parametrial or sidewall invasion) is treated with concurrent Cisplatin-based chemoradiation + brachytherapy.

If a patient undergoes a total hysterectomy (cervix removed) for benign disease (e.g., uterine fibroids or adenomyosis) and has no prior history of CIN 2/3 or cervical cancer, discontinue all future Pap and HPV screening permanently. Conversely, if a supracervical hysterectomy was performed (cervix left in situ) or if the hysterectomy was performed for CIN 2/3 or cervical malignancy, continued vaginal cuff/cervical cytology surveillance is required.

Both Müllerian Agenesis (MRKH) and Complete Androgen Insensitivity Syndrome (AIS) present as a phenotypic adolescent girl with primary amenorrhea, normal breast development, and an absent uterus with a blind-ending vaginal pouch on pelvic ultrasound. Three features immediately separate them on board exams: (1) Axillary and Pubic Hair: Present in Müllerian agenesis (intact androgen receptors respond to normal adrenal/ovarian androgens), but absent or sparse in AIS (defective androgen receptors cannot respond to androgens). (2) Serum Testosterone: Normal female range in Müllerian agenesis, versus elevated male range in AIS. (3) Karyotype & Gonads: 46,XX with normal ovaries in Müllerian agenesis (associated with renal anomalies), versus 46,XY with undescended testes in AIS (requiring gonadectomy after puberty completes).

After excluding pregnancy with a β-hCG, the initial blood work for secondary amenorrhea includes serum Prolactin, TSH, and FSH. Both Primary Hypothyroidism (high TRH stimulates lactotrophs to secrete prolactin) and Prolactinomas / Dopamine-antagonist antipsychotics (risperidone, haloperidol) cause hyperprolactinemia, which directly inhibits hypothalamic GnRH release (treat prolactinoma with cabergoline). If TSH and prolactin are normal, check FSH: an elevated FSH (>40 mIU/mL) before age 40 establishes Primary Ovarian Insufficiency (Premature Ovarian Failure, associated with FMR1 Fragile X premutation and autoimmune oophoritis). If FSH is normal/low and a 10-day progestin withdrawal challenge fails to induce bleeding despite estrogen priming, diagnose uterine outflow scarring (Asherman syndrome) following a prior D&C for postpartum hemorrhage or septic abortion.

When evaluating a woman with oligomenorrhea and hirsutism, compare the tempo of onset and serum hormone levels: PCOS begins gradually around menarche with mild hirsutism/acne and mildly elevated testosterone (<150 ng/dL) with normal DHEA-S. Conversely, rapid-onset virilization (clitoromegaly, temporal balding, deepening of the voice, male-pattern muscle bulk) indicates an androgen-secreting neoplasm: if serum Testosterone is >150–200 ng/dL with normal DHEA-S, suspect an ovarian Sertoli-Leydig cell tumor (order pelvic ultrasound); if serum DHEA-S is >700 μg/dL, suspect an adrenal cortical carcinoma/adenoma (order adrenal CT). If 17-hydroxyprogesterone is elevated, diagnose nonclassic 21-hydroxylase Congenital Adrenal Hyperplasia.

When an adnexal cyst or mass is palpated or discovered, transvaginal ultrasound (TVUS) is always the initial imaging test of choice. Simple, thin-walled, unilocular anechoic cysts ≤5–7 cm in premenopausal women are benign physiological follicular or corpus luteum cysts managed with reassurance or repeat ultrasound in 6–12 weeks (note: starting combined OCPs prevents new functional cysts from forming, but does NOT accelerate resolution of an existing cyst). Conversely, ultrasound features suspicious for malignancy include solid nodular components, thick septations (>2–3 mm), papillary projections, bilateral masses, and ascites. Crucially, NEVER perform percutaneous transabdominal needle biopsy of a suspected malignant ovarian mass because rupturing the capsule spills malignant cells into the peritoneal cavity and upstages the cancer; proceed directly to exploratory surgical staging (TAH-BSO, omentectomy, lymph node sampling) with paclitaxel plus carboplatin chemotherapy.

Ovarian Torsion occurs when an ovary rotates around its infundibulopelvic (suspensory) ligament and utero-ovarian ligament, most commonly precipitated by a benign Mature Cystic Teratoma (dermoid cyst) or corpus luteum cyst ≥5 cm acting as a heavy gravitational fulcrum. Because thin-walled, low-pressure veins and lymphatics compress before thick-walled muscular arteries, the ovary becomes massively edematous and congested while arterial Doppler pulses may still be intermittently detected. Therefore, in a patient presenting with sudden, severe unilateral lower quadrant pain radiating to the flank/groin, nausea, vomiting, and an enlarged edematous adnexal mass, proceed immediately to laparoscopic detorsion and ovarian cystectomy (saving the ovary unless frankly necrotic).

Whether unopposed estrogen arises from obesity (peripheral aromatase conversion of androstenedione to estrone), chronic anovulation in PCOS, unopposed estrogen hormone therapy, tamoxifen (partial estrogen agonist in endometrium), or an estrogen-secreting Granulosa-Theca cell ovarian tumor, persistent endometrial proliferation progresses through simple and complex atypical hyperplasia to Type I Endometrioid Adenocarcinoma (PTEN and mismatch repair mutations).

While the single most common overall cause of postmenopausal vaginal bleeding is benign vaginal/endometrial atrophy (~60–80%), roughly 10% of cases are caused by Endometrial Carcinoma. Therefore, every postmenopausal patient presenting with vaginal bleeding requires evaluation via either an immediate office Endometrial Biopsy or a Transvaginal Ultrasound (TVUS). On TVUS in a postmenopausal patient, an endometrial stripe thickness ≤4 mm has a >99% negative predictive value for endometrial cancer and can be observed (unless bleeding recurs, which mandates biopsy regardless of thickness). An endometrial thickness >4 mm in a postmenopausal woman mandates an Endometrial Biopsy.

Uterine Leiomyomas (Fibroids) are benign, estrogen- and progesterone-sensitive monoclonal smooth muscle tumors (whorled bundles of spindle cells; MED12 mutations; zero risk of malignant transformation into leiomyosarcoma, which arises de novo!). Clinical presentation depends on anatomic layer: Submucosal fibroids protrude into the endometrial cavity and cause heavy menstrual bleeding (menorrhagia) and recurrent miscarriage/infertility (treated with hysteroscopic myomectomy); Intramural fibroids are the most common and cause menorrhagia plus an irregularly enlarged, asymmetric, firm nodular uterus; Subserosal fibroids cause bulk pelvic pressure, constipation, or urinary frequency (or acute pain if pedunculated torsion or pregnancy red degeneration occurs). Medical therapy utilizes tranexamic acid, levonorgestrel IUD / OCPs, or preoperative GnRH agonists (Leuprolide) or antagonists (Elagolix/Relugolix) to shrink fibroids and correct anemia (≤6 months due to trabecular osteoporosis risk).

When behavioral bladder training fails in Urge Urinary Incontinence (Detrusor Overactivity), pharmacologic options include antimuscarinics (oxybutynin, tolterodine, solifenacin, which block M₃ receptors) and the β₃-adrenergic agonist Mirabegron (which relaxes the detrusor dome during bladder filling). In elderly patients (>65 years) or patients with dementia, narrow-angle glaucoma, gastroparesis, or chronic constipation, Mirabegron is strongly preferred over Oxybutynin because antimuscarinics cross the blood-brain barrier and precipitate acute delirium, falls, dry mouth, constipation, and urinary retention (Beers Criteria); note only that mirabegron is contraindicated in uncontrolled severe hypertension (≥180/110 mmHg).